Summit says FDA sets Nov. 14, 2026 action date for ivonescimab lung cancer filing
SMMT•FDA review begins for ivonescimab filing
Summit Therapeutics’ BLA for ivonescimab with platinum-doublet chemotherapy entered FDA review for EGFR-mutated advanced non-squamous NSCLC.
PDUFA goal action date set for Nov. 14, 2026.
